- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017
Conference call details are as follows:
| Date: | Tuesday, November 7, 2017 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 2479419 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starts at 7:30 p.m. ET, Nov. 7, 2017 until 7:30 p.m. ET, Nov. 14, 2017 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 2479419 |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until February 7, 2018 |
About Novavax
Contact:
Investor Relations
Director, Investor & Media Relations
[email protected]
240-268-2000
[email protected]
443-213-0506
Media
Russo Partners, LLC
[email protected]
[email protected]
212-845-4271
